PharmTech
CONTINUE TO SITE >

OR WAIT 15 SECS

DPT and Confab Complete $10 Million Capital Investment

March 8, 2016
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-04-06-2016, Volume 11, Issue 4

The investment includes facility upgrades and expansion of development capabilities.

DPT Laboratories, a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms, and Confab, a DPT company specializing in complex solids, semi-solids, and liquids, have completed a combined $10 million capital investment.

According to a press announcement from the company, DPT invested in a new compounding suite and upgrades to production filling lines. Additional upgrades include a remodeled front office area, enhanced security, and enhancement for further GMP compliance.

Confab, based in Montreal, made an investment to increase R&D capabilities with a new laboratory, new equipment, and expansion of its R&D team. According to a press announcement, Confab will now offer pharmaceutical development capabilities including formulation development, analytical method development, and technology transfers at commercial scale.

Source: DPT